Biocryst Pharmaceuticals Stock
Price
Target price
€8.96
€8.96
5.410%
0.462
5.410%
€17.26
11.08.26 / Tradegate
WKN: 896047 / Symbol: BCRX / Name: Biocryst Pharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals dominated the market today, gaining €0.46 (5.410%).
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Biocryst Pharmaceuticals.
As a result the target price of 17 € shows a very positive potential of 89.69% compared to the current price of 8.96 € for Biocryst Pharmaceuticals.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Biocryst Pharmaceuticals stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | 5.410% | 14.370% | -2.055% | 26.905% | 36.699% | 40.823% | -32.439% |
| Heron Therapeutics Inc. | -3.700% | -36.899% | -25.120% | -74.449% | -74.794% | -81.154% | -97.132% |
| Evolus Inc | 9.770% | 22.760% | 11.689% | 29.317% | 18.165% | -27.640% | -28.840% |
| Rhythm Pharmaceuticals | -2.010% | 7.065% | 3.684% | 26.282% | 5.348% | 303.689% | 764.035% |
Comments
BioCryst Pharmaceuticals (BCRX) had its price target lowered by Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target lowered by Wedbush from $21.00 to $20.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target raised by Royal Bank Of Canada from $13.00 to $14.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat